Leo Pharma enters collaboration with Canadian biotech firm
Sequence Bio, a Canadian biotech firm, has inked a deal with Danish Leo Pharma to collaborate on identifying new dermatological targets using the former company’s technology platform.
by ulrich quistgaard, translated by daniel pedersen
Danish pharmaceutical firm Leo Pharma has entered a collaboration agreement with Canadian biotech firm Sequence Bio to use the latter’s proprietary discovery platform to identify dermatological targets, Sequence Bio has announced in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
England and Wales reject Leo Pharma's eczema drug
For subscribers
.jpg&w=384&q=75)
